Amylin, Biocon team up to develop diabetes drug

SAN DIEGO Amylin Pharmaceuticals has partnered with an Indian drug maker to develop a diabetes drug using its peptide technology.

Amylin and Biocon announced Thursday that they would develop, commercialize and manufacture the drug using Amylin’s peptide hybrid, or “phybrid” technology.

Under the agreement, Amylin will provide its expertise in peptide hormone development and metabolic disease therapeutics, while Biocon will provide its expertise in recombinant microbial expression to manufacture the drug while using its experience in preclinical and clinical studies.

“This agreement fully leverages the synergistic capabilities of the two companies,” Biocon chairman and managing director Kiran Mazumdar-Shaw said in a statement.